Status:
COMPLETED
Miralax (PEG 3350) vs. Golytely as Bowel Preparation for Screening Colonoscopy
Lead Sponsor:
Temple University
Conditions:
Colon Cancer
Eligibility:
All Genders
40-75 years
Phase:
PHASE4
Brief Summary
A major limitation to the widespread acceptance of colonoscopy as a procedure to screen for colorectal cancer is the laxative preparation. Phosphate-based preps (e.g. Fleets Phosphosoda) are now used ...
Detailed Description
Objective To determine whether Miralax is as efficacious for bowel cleansing as standard Golytely for screening colonoscopy. This study is designed and powered to be an non-inferiority study. Primary...
Eligibility Criteria
Inclusion
- All adults undergoing average risk colon cancer screening (ages 40-75 years old)
- •Able to provide informed consent
Exclusion
- A history of constipation
- Patients who use medications to assist with a bowel movement such as osmotic, stimulant, or cathartic laxatives (including "colon cleansers")
- Diabetes or glucose intolerance
- Patients with severe underlying renal or hepatic impairment
- Pregnant women - pregnancy test performed on all menstruating women before procedure.
Key Trial Info
Start Date :
April 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2011
Estimated Enrollment :
136 Patients enrolled
Trial Details
Trial ID
NCT01170754
Start Date
April 1 2010
End Date
July 1 2011
Last Update
September 13 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Temple University Hospital
Philadelphia, Pennsylvania, United States, 19140